Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2022-05-18 Capital/Financing Update
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change involving a private placement financing by Tetra Bio-Pharma Inc. It includes dates of material change, description of the private placement, issuance of shares, and related corporate actions. The content focuses on a financing event and capital raising activity, including subscription agreements and share issuance details. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a simple announcement of a report but a detailed regulatory filing about a material change related to capital raising. This fits the category of Capital/Financing Update (CAP). The document length (8689 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-05-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received an Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for a novel topical therapeutic containing CBD. It discusses the regulatory milestone, the drug's development status, and background information about the disease and the company. There are no financial statements, earnings data, management discussion, or detailed regulatory filings. The content is primarily a corporate announcement about a regulatory designation related to drug development. This type of document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related news that do not fit into more specific categories like financial reports or management changes.
2022-05-18 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the first tranche of a private placement financing by Tetra Bio-Pharma with Cannvalate. It details the issuance of common shares, the subscription price, and the proceeds raised. It also discusses the partnership and clinical trials related to the company's drug development programs. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document focuses on capital raising and partnership updates, which aligns with a Capital/Financing Update. The length is about 7,863 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-05-17 English
News release - English.pdf
Regulatory Filings
2022-05-10 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a partnership agreement between Tetra Bio-Pharma and Cannvalate, including details of a private placement financing of CAD$7.5 million. It discusses the terms of the private placement, the clinical trials to be conducted, and the appointment of a special advisor to the board. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document focuses on a financing transaction and strategic partnership rather than reporting financial results or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing and partnership, not merely an announcement of a report or certification.
2022-05-05 English
Other.pdf
AGM Information Classification · 95% confidence The document is an instruction guide for shareholders on how to participate in a virtual meeting, including details on logging in, voting, and asking questions. It does not contain any financial data, management discussion, or report content. It is clearly related to the Annual General Meeting (AGM) process but is not the AGM presentation or materials themselves. Instead, it is a procedural notice on how to attend and participate in the AGM online. Given the content and length (3095 characters), it is not a full report or transcript but an informational document related to the AGM event. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-04-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.